Total joint arthroplasties (TJA), such as hip and joint replacements, are among the most common surgical procedures worldwide, with over 4,3 million performed annually in OECD countries. This number is expected to increase by 12-50% by 2050. The growing prevalence of TJA has led to a rise in complications (~12% of all surgeries), particularly periprosthetic joint infections (PJI), which occur in 1-2% of patients and is a major cause of surgery revisions. PJI results not only in morbidity and prolonged hospital stays but also a substantial financial burden on healthcare systems. Nevertheless, there is an unmet need for a solution that specifically diagnoses PJI in a timely and cost-effective manner. Current diagnostic methods for PJI are inadequate due to low sensitivity, specificity, long turnaround times, restriction to specific bacterial strains, and high costs. TAmiRNA has developed promiR, the first-in-class microRNA-based biomarker test, which offers near 100% accuracy in diagnosing PJI. promiR stands out by its unique integration of biological and technological innovations. It combines the detection of microRNAs, which are released during the response to infection from the joint tissue as well as immune cells, into a one-stop, streamlined solution, thereby ensuring a precise and reliable diagnosis of PJI. TAmiRNA’s B2B framework plans to introduce promiR in 15 countries from 2027 to 2028, outsourcing manufacturing and distribution. This presents a multimillion market opportunity, with a TAM of €645 million and an initial SAM of €77,5 million. Moreover, assuming a 2032 average market share of 35% in the 15 countries, the SOM will be €28,3 million. EIC funding is crucial for accelerating innovation by closing technological gaps, facilitating regulatory compliance, and successful commercialization of promiR, ultimately revolutionizing PJI diagnostics and improving patient outcomes.